戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 fants with established chronic lung disease (bronchopulmonary dysplasia).
2 inopathy of prematurity stage 3-5, or severe bronchopulmonary dysplasia).
3  TGF-beta signaling, ultimately resulting in bronchopulmonary dysplasia.
4 nistration did not alter the early course of bronchopulmonary dysplasia.
5                      A composite of death or bronchopulmonary dysplasia.
6  how to prevent fetal lung injury leading to bronchopulmonary dysplasia.
7 ng hypotheses about the molecular origins of bronchopulmonary dysplasia.
8 atory syncytial virus infection, asthma, and bronchopulmonary dysplasia.
9 ctly contribute to disrupted angiogenesis in bronchopulmonary dysplasia.
10 irus, airway hyperresponsiveness, and severe bronchopulmonary dysplasia.
11 atory syncytial virus infection, asthma, and bronchopulmonary dysplasia.
12 ed lung injury in a murine neonatal model of bronchopulmonary dysplasia.
13  weeks of postmenstrual age or survival with bronchopulmonary dysplasia.
14 ponsible for neonatal lung injury leading to bronchopulmonary dysplasia.
15 ficant difference in the outcome of death or bronchopulmonary dysplasia.
16 bility to postnatal normoxia, reminiscent of bronchopulmonary dysplasia.
17 2 is also increased in neonates that develop bronchopulmonary dysplasia.
18 00 g does not decrease the rates of death or bronchopulmonary dysplasia.
19 ncidence of pneumonia and the development of bronchopulmonary dysplasia.
20  have been implicated in the pathogenesis of bronchopulmonary dysplasia.
21 ed lung injury using a fetal baboon model of bronchopulmonary dysplasia.
22 nstitutes of Health Collaborative Project on Bronchopulmonary Dysplasia.
23 hma stimulated its use in infants to prevent bronchopulmonary dysplasia.
24  secondary outcomes, including mortality and bronchopulmonary dysplasia.
25 respiratory illness in preterm children with bronchopulmonary dysplasia.
26 eucomalacia, retinopathy of prematurity, and bronchopulmonary dysplasia.
27 ns with PPHN, congenital heart diseases, and bronchopulmonary dysplasia.
28 ng factor in neonatal lung injury leading to bronchopulmonary dysplasia.
29  are prone to lung injury that may result in bronchopulmonary dysplasia.
30 a/Q . , and shunt to preterm infants without bronchopulmonary dysplasia.
31 arance of phenotypical changes suggestive of bronchopulmonary dysplasia.
32 itric oxide therapy reduced the incidence of bronchopulmonary dysplasia (29.8 percent vs. 59.6 percen
33 ta were available, 191 died or survived with bronchopulmonary dysplasia (38.4%), as compared with 180
34  risk difference, -3.3 to 4.5; P = .70), and bronchopulmonary dysplasia (4.4% vs 5.1%; 95% CI of risk
35 itis (48.1%, 37.1%, and 32.5%), and death or bronchopulmonary dysplasia (74.9%, 68.9%, and 65.5%).
36 cumulate in the lungs of infants with severe bronchopulmonary dysplasia, a chronic lung disease assoc
37 posure to inflammation increases the risk of bronchopulmonary dysplasia, a chronic, developmental lun
38            Premature infants are at risk for bronchopulmonary dysplasia, a complex condition characte
39 nsufficient generation of alveoli results in bronchopulmonary dysplasia, a disease of prematurity.
40 ciated with a lower likelihood of developing bronchopulmonary dysplasia, a sequelae of RDS (p<0.03).
41 61.6%) in the placebo group survived without bronchopulmonary dysplasia (absolute difference, -5.0% [
42 ria that best predicted this outcome defined bronchopulmonary dysplasia according to treatment with t
43 ased odds of a composite outcome of death or bronchopulmonary dysplasia (adjusted odds ratio [AOR], 0
44 nd immunogenic and may protect children with bronchopulmonary dysplasia against serious RSV disease o
45 achypnea of the newborn, surfactant use, and bronchopulmonary dysplasia also occurred significantly l
46 emic glucocorticoids reduce the incidence of bronchopulmonary dysplasia among extremely preterm infan
47 tive lung vascular development can result in bronchopulmonary dysplasia and alveolar capillary dyspla
48 premature infants is a major risk factor for bronchopulmonary dysplasia and can impair the host respo
49 orn and developmental lung diseases, such as bronchopulmonary dysplasia and congenital diaphragmatic
50                                              Bronchopulmonary dysplasia and emphysema are life-threat
51 2 were decreased in airways of neonates with bronchopulmonary dysplasia and in mice after airway inju
52 crease oxygen demands in these infants, like bronchopulmonary dysplasia and increased oxygen consumpt
53 iciously, weighing up the competing risks of bronchopulmonary dysplasia and neurodevelopmental harm.
54 ed with a reduction in the rates of death or bronchopulmonary dysplasia and patent ductus arteriosus.
55 cted), independent of degree of prematurity, bronchopulmonary dysplasia and postnatal sepsis.
56 Evidence suggests that preterm neonates with bronchopulmonary dysplasia and prolonged mechanical vent
57 may explain the complex relationship between bronchopulmonary dysplasia and retinopathy of prematurit
58 on groups were low-risk VLBW infants without bronchopulmonary dysplasia and term infants (>36 weeks,
59 d from EP subjects with and without neonatal bronchopulmonary dysplasia and term-born control subject
60 ns of systemic dexamethasone used to prevent bronchopulmonary dysplasia and thus more restricted use,
61 rtality, enlarged alveolar spaces resembling bronchopulmonary dysplasia, and altered expression of ge
62       One child died of a thoracic tumor and bronchopulmonary dysplasia, and another died of acute my
63 h-risk VLBW infants were diagnosed as having bronchopulmonary dysplasia, and comparison groups were l
64 th respiratory distress syndromes, including bronchopulmonary dysplasia, and differential gene expres
65 y hypertension in pediatric diseases such as bronchopulmonary dysplasia, and increasingly expanding d
66 g enterocolitis, retinopathy of prematurity, bronchopulmonary dysplasia, and intraventricular hemorrh
67  pulmonary disease, asthma, cystic fibrosis, bronchopulmonary dysplasia, and muscular dystrophies.
68 idities such as intraventricular hemorrhage, bronchopulmonary dysplasia, and necrotizing enterocoliti
69 m, briefly explore pulmonary hypertension in bronchopulmonary dysplasia, and provide updates on the d
70 iratory parameters were worse after neonatal bronchopulmonary dysplasia, and respiratory function dif
71 ing arrested alveolar growth in experimental bronchopulmonary dysplasia, and that exogenous ECFCs res
72 atory syncytial virus infection, asthma, and bronchopulmonary dysplasia; and genotyped and analyzed i
73                       Several definitions of bronchopulmonary dysplasia are clinically used; however,
74                           Measures to reduce bronchopulmonary dysplasia are not always effective or h
75 hoc analyses suggest that rates of death and bronchopulmonary dysplasia are reduced for infants with
76 ion) were classified as having physiological bronchopulmonary dysplasia, as compared with 269 (43.9%)
77 tional involvement of pulmonary apoptosis in bronchopulmonary dysplasia- associated alveolar disrupti
78              The primary outcome measure was bronchopulmonary dysplasia at 28 days of age.
79     The primary outcome was survival without bronchopulmonary dysplasia at 36 weeks of postmenstrual
80                 The rate of survival without bronchopulmonary dysplasia at 36 weeks of postmenstrual
81 efficacy outcome was a composite of death or bronchopulmonary dysplasia at 36 weeks of postmenstrual
82                  Secondary outcomes included bronchopulmonary dysplasia at 36 weeks of postmenstrual
83 cidence of the composite outcome of death or bronchopulmonary dysplasia at 36 weeks' postmenstrual ag
84             The combined outcome of death or bronchopulmonary dysplasia at 36 weeks' postmenstrual ag
85                                              Bronchopulmonary dysplasia based on a clinical definitio
86 ated no difference in death or survival with bronchopulmonary dysplasia between nasal intermittent po
87 cant difference in the incidence of death or bronchopulmonary dysplasia between patients receiving in
88 R], 12.37; 95% CI, 1.92-79.63; P = .001) and bronchopulmonary dysplasia (BPD) (6 of 6 [100%] vs 55 of
89                      The primary outcome was bronchopulmonary dysplasia (BPD) among survivors.
90 remature labor and, among VLBW infants, with bronchopulmonary dysplasia (BPD) and chronic lung diseas
91 tion damage resulting in a high incidence of bronchopulmonary dysplasia (BPD) and chronic respiratory
92  decreased capillary density in infants with bronchopulmonary dysplasia (BPD) and in BPD-like animal
93 th of life are independently associated with bronchopulmonary dysplasia (BPD) and long-term respirato
94 y, are associated with an increased risk for bronchopulmonary dysplasia (BPD) and pulmonary hypertens
95                         Preterm infants with bronchopulmonary dysplasia (BPD) and pulmonary hypertens
96 k factors associated with increased risk for bronchopulmonary dysplasia (BPD) and respiratory disease
97                                              Bronchopulmonary dysplasia (BPD) and retinopathy of prem
98 o associate two key antecedent risk factors, bronchopulmonary dysplasia (BPD) and retinopathy of prem
99 st week of life reduces the rate of death or bronchopulmonary dysplasia (BPD) but may cause long-term
100              Autopsied lungs of infants with bronchopulmonary dysplasia (BPD) demonstrate impaired al
101  neonatologists on the role of Ureaplasma in bronchopulmonary dysplasia (BPD) development, the use of
102 emature infants and changed the pathology of bronchopulmonary dysplasia (BPD) from one of acute lung
103                                              Bronchopulmonary dysplasia (BPD) has multifactorial etio
104 cigarette smoke increases the risk of AA and bronchopulmonary dysplasia (BPD) in children and animal
105  is a key contributor to the pathogenesis of bronchopulmonary dysplasia (BPD) in neonates, for which
106   Systemic sepsis is a known risk factor for bronchopulmonary dysplasia (BPD) in premature infants, a
107                     The clinical syndrome of bronchopulmonary dysplasia (BPD) in preterm infants resu
108 itamin A supplementation reduced the risk of bronchopulmonary dysplasia (BPD) in very-low-birth-weigh
109                                              Bronchopulmonary dysplasia (BPD) involves macrophage-dri
110                                              Bronchopulmonary dysplasia (BPD) is a chronic disease of
111                                              Bronchopulmonary dysplasia (BPD) is a chronic lung disea
112                                              Bronchopulmonary dysplasia (BPD) is a chronic lung disea
113                                              Bronchopulmonary dysplasia (BPD) is a chronic lung disea
114                                              Bronchopulmonary dysplasia (BPD) is a chronic lung disea
115                                              Bronchopulmonary dysplasia (BPD) is a chronic lung disea
116                                              Bronchopulmonary dysplasia (BPD) is a chronic lung disea
117                                              Bronchopulmonary dysplasia (BPD) is a chronic respirator
118                                              Bronchopulmonary dysplasia (BPD) is a common adverse out
119                                              Bronchopulmonary dysplasia (BPD) is a common complicatio
120                                              Bronchopulmonary dysplasia (BPD) is a common lung diseas
121                                              Bronchopulmonary dysplasia (BPD) is a disease prevalent
122                                              Bronchopulmonary dysplasia (BPD) is a frequent complicat
123                                   Rationale: Bronchopulmonary dysplasia (BPD) is a leading complicati
124                                              Bronchopulmonary dysplasia (BPD) is a major complication
125                                              Bronchopulmonary dysplasia (BPD) is a prevalent yet poor
126                                              Bronchopulmonary dysplasia (BPD) is characterized by lif
127                                              Bronchopulmonary dysplasia (BPD) is often associated wit
128                                              Bronchopulmonary dysplasia (BPD) is the most common chro
129                                              Bronchopulmonary dysplasia (BPD) is the most common chro
130                                              Bronchopulmonary dysplasia (BPD) is the most common in-h
131                                              Bronchopulmonary dysplasia (BPD) is the most common morb
132              School-age children who survive bronchopulmonary dysplasia (BPD) may have a permanent re
133                                              Bronchopulmonary dysplasia (BPD) occurs in approximately
134 ith Ureaplasma parvum is causally related to bronchopulmonary dysplasia (BPD) or adverse respiratory
135                                              Bronchopulmonary dysplasia (BPD) rates in the United Sta
136                                              Bronchopulmonary dysplasia (BPD) remains a major respira
137                                              Bronchopulmonary dysplasia (BPD) remains a serious morbi
138                                              Bronchopulmonary dysplasia (BPD) remains the most common
139 dysfunction is strongly associated with high bronchopulmonary dysplasia (BPD) risk in preterm infants
140 redict which premature infants would develop bronchopulmonary dysplasia (BPD) than single measurement
141 r example, we have shown in a mouse model of bronchopulmonary dysplasia (BPD) that mesenchymal stem c
142 levels are elevated in newborns that develop bronchopulmonary dysplasia (BPD), a chronic lung disease
143                                              Bronchopulmonary dysplasia (BPD), a chronic lung disease
144                              The etiology of bronchopulmonary dysplasia (BPD), a chronic lung disease
145 s a major contributor to the pathogenesis of bronchopulmonary dysplasia (BPD), a chronic lung disease
146 vents normal lung morphogenesis and leads to bronchopulmonary dysplasia (BPD), a common complication
147                          The pathogenesis of bronchopulmonary dysplasia (BPD), a devastating lung dis
148 ck of Pdgfra arrested alveologenesis akin to bronchopulmonary dysplasia (BPD), a neonatal chronic lun
149 e and chronic pulmonary disorders, including bronchopulmonary dysplasia (BPD), a respiratory conditio
150                                              Bronchopulmonary dysplasia (BPD), also called chronic lu
151 s associated with a high risk for developing bronchopulmonary dysplasia (BPD), but its relationship w
152  significantly to morbidity and mortality in bronchopulmonary dysplasia (BPD), but little is known ab
153 ith poor outcomes among preterm infants with bronchopulmonary dysplasia (BPD), but whether early sign
154 term complications of prematurity, including bronchopulmonary dysplasia (BPD), cause mortality and mo
155 evelop a chronic form of lung disease called bronchopulmonary dysplasia (BPD), characterized by decre
156 and worsened respiratory outcomes, including bronchopulmonary dysplasia (BPD), in preterm infants.
157     Outcomes included 28-day survival/death, bronchopulmonary dysplasia (BPD), periventricular/intrav
158  lung disease of early infancy, often called bronchopulmonary dysplasia (BPD), remains unclear, partl
159                                              Bronchopulmonary dysplasia (BPD), the main consequence o
160 re during gestation may increase the risk of bronchopulmonary dysplasia (BPD)-a developmental lung co
161                                              Bronchopulmonary dysplasia (BPD)-associated pulmonary hy
162                     Rationale: Patients with bronchopulmonary dysplasia (BPD)-associated pulmonary hy
163 ematurity suffering the most severe forms of bronchopulmonary dysplasia (BPD).
164 ality of chronic lung disease of infancy, or bronchopulmonary dysplasia (BPD).
165 ogenesis, leading to chronic lung disease or Bronchopulmonary dysplasia (BPD).
166 cells in inflammatory lung diseases, such as bronchopulmonary dysplasia (BPD).
167 -ALRI in children less than 5 years old with bronchopulmonary dysplasia (BPD).
168 s have long sought preventive treatments for bronchopulmonary dysplasia (BPD).
169 inhibition of lung growth that characterizes bronchopulmonary dysplasia (BPD).
170 ) are elevated in newborns who later develop bronchopulmonary dysplasia (BPD).
171 vasculature may be an important component of bronchopulmonary dysplasia (BPD).
172 n tracheal aspirates of newborns who develop bronchopulmonary dysplasia (BPD).
173 onged pulmonary inflammation and fibrosis in bronchopulmonary dysplasia (BPD).
174 h severe pediatric lung disorders, including bronchopulmonary dysplasia (BPD).
175 periods of supplemental oxygen and developed bronchopulmonary dysplasia (BPD).
176 ies associated with preterm birth, including bronchopulmonary dysplasia (BPD).
177              A borderline viability model of bronchopulmonary dysplasia (BPD)/chronic lung disease of
178 athways in three pulmonary diseases (asthma; bronchopulmonary dysplasia (BPD); and chronic obstructiv
179                Length of stay increased with bronchopulmonary dysplasia (BPD; 1.77), whereas total co
180 ften develop chronic lung dysfunction termed bronchopulmonary dysplasia (BPD; also known as chronic l
181 neutrophil-driven disease of ECM remodeling (bronchopulmonary dysplasia [BPD]).
182 mon aspects in the genetic predisposition to bronchopulmonary dysplasia, bronchiolitis, and childhood
183  no significant difference in the outcome of bronchopulmonary dysplasia but a potential reduction in
184 as been reported to improve survival without bronchopulmonary dysplasia but its safety with regard to
185 Early beclomethasone therapy did not prevent bronchopulmonary dysplasia but was associated with lower
186 turated fatty acid, might reduce the risk of bronchopulmonary dysplasia, but appropriately designed t
187 enoic acid (DHA) supplementation may prevent bronchopulmonary dysplasia, but evidence remains inconcl
188 m 50% to 16% (p = 0.002) among children with bronchopulmonary dysplasia, but it increased from 14% to
189 ted ventilation and reduces the incidence of bronchopulmonary dysplasia, but its effects on respirato
190           Arrested lung development leads to bronchopulmonary dysplasia, but the molecular pathways t
191 al lung macrophage activation contributes to bronchopulmonary dysplasia by generating a localized inf
192                                 Diagnosis of bronchopulmonary dysplasia by standard criteria was reco
193  segregated from those infants who developed bronchopulmonary dysplasia by the magnitude of the epith
194                                     Defining bronchopulmonary dysplasia by the use of oxygen alone is
195                       Premature infants with bronchopulmonary dysplasia, characterized by interrupted
196 sitive and specific index of the severity of bronchopulmonary dysplasia.Conclusions: Most infants wit
197             The primary outcome was death or bronchopulmonary dysplasia, confirmed by means of standa
198 olar enlargement, which is characteristic of bronchopulmonary dysplasia, congenital matrix disorders,
199                                              Bronchopulmonary dysplasia continues to be an important
200 evere, acute respiratory distress; this "new bronchopulmonary dysplasia" could be the result of impai
201  function and morphology in animal models of bronchopulmonary dysplasia, creating a rationale for cli
202                          Various traditional bronchopulmonary dysplasia criteria based on respiratory
203                                       Severe bronchopulmonary dysplasia/death rates at 36 weeks' post
204                      The primary outcome was bronchopulmonary dysplasia, defined on a physiological b
205                           Infants developing bronchopulmonary dysplasia demonstrate an early pulmonar
206 val to 36 weeks of postmenstrual age without bronchopulmonary dysplasia did not differ significantly
207  present in the lungs of patients developing bronchopulmonary dysplasia disrupt expression of multipl
208 xide did not reduce the overall incidence of bronchopulmonary dysplasia, except among infants with a
209                                              Bronchopulmonary dysplasia, family history of asthma, sm
210 eonatal period did not significantly improve bronchopulmonary dysplasia-free survival at 36 weeks' po
211                      The primary outcome was bronchopulmonary dysplasia-free survival in infants at 3
212 1P in the pathobiological characteristics of bronchopulmonary dysplasia has not been investigated.
213    Infants with a history of prematurity and bronchopulmonary dysplasia have a high risk of asthma an
214 g mesenchymal stromal cell (MSC) therapy for bronchopulmonary dysplasia have been initiated; however,
215 ary dysplasia.Conclusions: Most infants with bronchopulmonary dysplasia have impaired oxygenation qua
216 ted to the respiratory distress syndrome and bronchopulmonary dysplasia in 2008-2011 than in 2000-200
217 e Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia in Extremely Preterm Infants)
218 e were seen from birth to the development of bronchopulmonary dysplasia in extremely preterm infants.
219                        To reduce the risk of bronchopulmonary dysplasia in extremely-low-birth-weight
220 ith the alveolar simplification phenotype of bronchopulmonary dysplasia in premature human infants an
221                                              Bronchopulmonary dysplasia in premature infants is assoc
222 nagement strategy to decrease morbidity from bronchopulmonary dysplasia in premature infants.
223 cocorticoids would decrease the frequency of bronchopulmonary dysplasia in premature infants.
224 and blunted lung development associated with bronchopulmonary dysplasia in preterm infants.
225 ed nitric oxide reduced the rate of death or bronchopulmonary dysplasia in such infants.
226                     Dexamethasone to prevent bronchopulmonary dysplasia in very preterm neonates was
227     Rates of other morbidities declined, but bronchopulmonary dysplasia increased between 2009 and 20
228  several morbidities were observed, although bronchopulmonary dysplasia increased.
229 eased and V . a/Q . decreased as severity of bronchopulmonary dysplasia increased.
230 lations of respiratory distress syndrome and bronchopulmonary dysplasia infants could be differentiat
231 bidities such as retinopathy of prematurity, bronchopulmonary dysplasia, injury to the developing bra
232                                              Bronchopulmonary dysplasia is a chronic lung disease obs
233                                              Bronchopulmonary dysplasia is a chronic lung disease of
234                                              Bronchopulmonary dysplasia is a chronic lung disease tha
235                                              Bronchopulmonary dysplasia is a common complication of p
236                                              Bronchopulmonary dysplasia is a common pulmonary complic
237                                   Rationale: Bronchopulmonary dysplasia is a heterogeneous lung disea
238                                     Although bronchopulmonary dysplasia is characterized histological
239 e use of this therapy in infants at risk for bronchopulmonary dysplasia is controversial.
240 ed, there is an increased risk of developing bronchopulmonary dysplasia, leading to significant respi
241 hyperoxic exposure, a predisposing factor to bronchopulmonary dysplasia, modulates the innate immune
242 sease (n=6), bronchiolitis obliterans (n=2), bronchopulmonary dysplasia (n=1), graft failure due to v
243 , neurodevelopmental outcomes, hearing loss, bronchopulmonary dysplasia, necrotizing enterocolitis, a
244 s were the individual composites of death or bronchopulmonary dysplasia, necrotizing enterocolitis, r
245 ric), a composite of death, brain injury, or bronchopulmonary dysplasia (neonatal), and a standardise
246                                 The rates of bronchopulmonary dysplasia, neurodevelopmental outcomes,
247 dless of prior or current oxygen therapy: no bronchopulmonary dysplasia, no support (n = 773); grade
248  occurred in 20/492 (4.1%) vs 28/518 (5.4%); bronchopulmonary dysplasia occurred in 130/458 (28.4%) v
249 eks of postmenstrual age, moderate or severe bronchopulmonary dysplasia occurred in 176 of 274 (64.2%
250                                              Bronchopulmonary dysplasia occurred in 41.7% of survivin
251 on is relevant to clinical disorders such as bronchopulmonary dysplasia of premature babies and lung
252                                              Bronchopulmonary dysplasia of the premature newborn is c
253       The composite outcome of physiological bronchopulmonary dysplasia or death before 36 weeks of p
254                                              Bronchopulmonary dysplasia or death prior to 36 weeks' p
255 selected cohorts (eg, only participants with bronchopulmonary dysplasia) or in which few participants
256 morrhage, sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, or death or in the frequency
257 rrhage, surgery for abdominal complications, bronchopulmonary dysplasia, or retinopathy of prematurit
258 n rates of necrotizing enterocolitis, severe bronchopulmonary dysplasia, or severe cerebral lesions w
259 erences in necrotizing enterocolitis, severe bronchopulmonary dysplasia, or severe cerebral lesions.
260 es are seen in airway samples and blood from bronchopulmonary dysplasia patients, the innate immune r
261 ate-onset sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, periventricular leucomalacia
262 alveolar growth-arrested rat lungs mimicking bronchopulmonary dysplasia proliferated less, showed dec
263 or in an array of pulmonary diseases such as bronchopulmonary dysplasia, pulmonary hypertension, and
264 nsplantation include pulmonary hypertension, bronchopulmonary dysplasia, pulmonary vein stenosis, and
265 ate data were available (46.3%), died or had bronchopulmonary dysplasia (relative risk, stratified ac
266   Rationale: Current diagnostic criteria for bronchopulmonary dysplasia rely heavily on the level and
267  cystic periventricular leukomalacia, severe bronchopulmonary dysplasia, retinopathy of prematurity (
268 erences in death or disability at 24 months, bronchopulmonary dysplasia, retinopathy of prematurity,
269 ROS-induced diseases of the newborn, such as bronchopulmonary dysplasia, retinopathy of prematurity,
270 95% CI, 0.14-0.28), the presence of neonatal bronchopulmonary dysplasia (score difference, -0.16; 95%
271 utcomes, which included perinatal mortality, bronchopulmonary dysplasia, sepsis, intraventricular hae
272 al morbidities (pulmonary hemorrhage, severe bronchopulmonary dysplasia, severe cerebral lesions, and
273 severe necrotizing enterocolitis, infection, bronchopulmonary dysplasia, severe intracranial hemorrha
274 luding severe respiratory distress syndrome, bronchopulmonary dysplasia, severe intraventricular hemo
275 or apnea of prematurity reduces the rates of bronchopulmonary dysplasia, severe retinopathy, and neur
276  not result in a lower risk of physiological bronchopulmonary dysplasia than a control emulsion among
277 al impairment.Conclusions: The definition of bronchopulmonary dysplasia that best predicted early chi
278        To identify the optimal definition of bronchopulmonary dysplasia that best predicts respirator
279 h of 18 prespecified, revised definitions of bronchopulmonary dysplasia that variably define disease
280                            When adjusted for bronchopulmonary dysplasia, the difference in flow rates
281  such as bronchiolitis, cystic fibrosis, and bronchopulmonary dysplasia, their use is controversial a
282 ased stepwise from 10% among infants without bronchopulmonary dysplasia to 77% among those with grade
283 exchange in preterm infants with and without bronchopulmonary dysplasia to grade disease severity and
284                     While infants developing bronchopulmonary dysplasia typically exhibited increased
285                             The incidence of bronchopulmonary dysplasia was 27.8% in the budesonide g
286 rval, 0.86 to 1.06; P=0.52), and the rate of bronchopulmonary dysplasia was 60 percent versus 68 perc
287                         The rate of death or bronchopulmonary dysplasia was 80 percent in the nitric
288                                              Bronchopulmonary dysplasia was defined as continuous sup
289  extremely preterm infants, the incidence of bronchopulmonary dysplasia was lower among those who rec
290  week, necrotizing enterocolitis, and severe bronchopulmonary dysplasia was seen in the screening era
291                             The frequency of bronchopulmonary dysplasia was similar in the two groups
292 izing enterocolitis, systemic infections and bronchopulmonary dysplasia were associated with altered
293  those characteristics of infants developing bronchopulmonary dysplasia were evaluated by masked comp
294 sedated, quiet-breathing infants with severe bronchopulmonary dysplasia were reconstructed into end-i
295 cal cord blood, and blood from newborns with bronchopulmonary dysplasia, were conducted both with and
296 ther species between infants with or without bronchopulmonary dysplasia when isolated alone.
297 me for premature infants who are at risk for bronchopulmonary dysplasia when it is started between 7
298                                 Infants with bronchopulmonary dysplasia who still require oxygen can
299 chanical ventilation and reduced severity of bronchopulmonary dysplasia without an increase in advers
300 A sensitive outcome measure for infants with bronchopulmonary dysplasia would facilitate clinical ben

 
Page Top